Cardiac-resynchronization therapy for mild-to-moderate heart failure.

By A. Tang, G. Wells, M. Talajic, M. Arnold, R. Sheldon, S. Connolly, S. Hohnloser, G. Nichol, D. Birnie, J. Sapp and 3 more. New England Journal of Medicine, 2010

1,699 citations recorded by the source corpus.

Subfields: Biomedical Engineering, Cardiology and Cardiovascular Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/7c7e9942ee439b68b2543620dc7880c9fd856ceb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

Citations in the corpus

2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2013, background): “Both for GDMT and other recommended drug treatment regimens, the reader is advised to confirm dosages with product insert material and to evaluate carefully for contraindications and drug-drug interactions.”
2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). (2013, methodology): “Pre-speciﬁed subgroup analyses of data collected in the MADIT-CRT, REVERSE and Resynchronization–Deﬁbrillation for Ambulatory Heart Failure Trial (RAFT) trials demonstrated that patients with a QRS duration ≥ 150 ms beneﬁted most from CRT. 50,61,62 Meta-analyses using aggregate data from randomized ”
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 (2012, methodology): “† Two key placebo-controlled RCTs randomized 3618 patients with mild (MADIT-CRT, 15% NYHA class I and 85% NYHA class II) to moderately [Resynchronization/Defibrillation for Ambulatory Heart Failure Trial (RAFT), 80% NYHA class II and 20% NYHA class III] symptomatic HF to either optimal medical thera”
2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. (2013, background): “Measurement of BNP or NT-proBNP and/or cardiac troponin is useful for establishing prognosis or disease severity in acutely decompensated HF (248, 251-258).”